JSA advised and assisted Lupin Limited (“Lupin”) in the acquisition of five legacy brands in strategic therapy areas – Gastroenterology, Urology and Anti-infectives from Menarini, along with their associated trademark rights. The brands are Piclin(Picosulphate Sodium), Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine) and Distaclor (Cefaclor).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. It enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the United States of America by prescriptions.
The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over $4.4 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 R&D centres, Menarini’s products are available in 140 countries worldwide.
Our Transaction Team Comprised Lead Partner – Shivpriya Nanda, Partner – Zain Pandit and Gaurav G Arora, Associate – Twisha Shrivastava and Vibhu Choubey.
Gaurav’s practice covers mergers & acquisitions, private equity, corporate structuring and restructuring, and general corporate commercial matters (including data privacy and white-collar crime investigations).